– October 1, 2006
October 1, 2006
View Issues
-
Metronomic Cyclophosphamide Adds Value to Neoadjuvant Hormonal Therapy for Elderly Breast Cancer Patients
In a trial in elderly women with breast cancer, primary systemic (neoadjuvant) therapy with letrozole with or without low dose daily oral cyclophosphamide was shown to increase overall clinical response. -
Resecting the Primary When Patients Present with Metastatic Breast Cancer: The Swiss Experience
The role of primary tumor resection for those who present with disseminated breast cancer has not been established. -
KIT Mutations Confer Worse Prognosis in Core Binding Factor Leukemias
Core binding factor (CBF) AML (eg, inversion 16 and translocation 8;21) has generally been considered favorable risk although the 50% long-term survival demonstrates the need for better delineating high-risk subsets. -
Adding Rituximab to CHOP for HIV-Lymphoma: Do the Benefits Outweigh the Risks?
Patients with HIV-associated non-Hodgkin's lymphoma have been successfully treated with chemotherapy since the advent of more effective anti-retroviral combinations. -
Breast Cancer Risk in the WHI Estrogen-Progestin Trial Arm
The WHI reports an increase in breast cancer is concentrated in prior hormone users, but the overall adjusted risk of breast cancer is not statistically significant. -
Pharmacology Watch
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998. -
Clinical Briefs in Primary Care Supplement